Michele Maio
Overview
Explore the profile of Michele Maio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
231
Citations
32871
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diab A, Ascierto P, Maio M, Abdel-Wahab R, Negrier S, Mortier L, et al.
J Clin Oncol
. 2025 Mar;
:JCO2400727.
PMID: 40048691
Purpose: There are limited treatment options for advanced melanoma that have progressed during or after immune checkpoint inhibitor therapy. Intratumoral (IT) immunotherapy may improve tumor-specific immune activation by promoting local...
2.
Marabelle A, OMalley D, Hendifar A, Ascierto P, Motola-Kuba D, Penel N, et al.
Nat Cancer
. 2025 Feb;
6(2):253-258.
PMID: 39979665
The phase 2 trial KEYNOTE-158 ( NCT02628067 ) evaluated pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient (MSI-H/dMMR) noncolorectal tumors. With 373 participants (95% with baseline MSI/dMMR documentation) and 4.5 years of follow-up,...
3.
Lofiego M, Tufano R, Bello E, Solmonese L, Marzani F, Piazzini F, et al.
J Exp Clin Cancer Res
. 2025 Feb;
44(1):58.
PMID: 39966970
Background: Co-targeting of immune checkpoint inhibitors (ICI) CTLA-4 and PD-1 has recently become the new first-line standard of care therapy of pleural mesothelioma (PM) patients, with a significant improvement of...
4.
Montico B, Giurato G, Guerrieri R, Colizzi F, Salvati A, Nassa G, et al.
J Exp Clin Cancer Res
. 2025 Feb;
44(1):53.
PMID: 39953610
Background: About 50% of cutaneous melanoma (CM) harbors the activating BRAF mutation which exerts most of the oncogenic effects through the MAPK signaling pathway. In the last years, a number...
5.
OMalley D, Bariani G, Cassier P, Marabelle A, Hansen A, Acosta A, et al.
Gynecol Oncol
. 2025 Jan;
193:130-135.
PMID: 39847999
Objective: We report updated results with longer follow-up in patients with MSI-H/dMMR endometrial cancer (EC) in cohort D (advanced EC of any MSI/dMMR status) and cohort K (any MSI-H/dMMR advanced...
6.
Mortier L, Villabona L, Lawrence B, Arance A, Butler M, Beylot-Barry M, et al.
Am J Clin Dermatol
. 2024 Oct;
25(6):987-996.
PMID: 39377880
Background: The phase III KEYNOTE-913 study was conducted to evaluate the efficacy and safety of pembrolizumab as first-line therapy in patients with advanced Merkel cell carcinoma (MCC). Objective: The aim...
7.
Wolchok J, Chiarion-Sileni V, Rutkowski P, Cowey C, Schadendorf D, Wagstaff J, et al.
N Engl J Med
. 2024 Sep;
392(1):11-22.
PMID: 39282897
Background: Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced melanoma. Given...
8.
Valente M, Colucci M, Vegni V, Croce V, Bellan C, Rossi G, et al.
Onco Targets Ther
. 2024 Aug;
17:673-681.
PMID: 39188308
Purpose: Treatment with immune-checkpoint inhibitors (ICIs) can be associated with a wide spectrum of immune-related adverse events (irAEs). Among irAEs, immune-mediated pneumonitis (im-PN) is a rare but potentially life-threatening side...
9.
Schenker M, Burotto M, Richardet M, Ciuleanu T, Goncalves A, Steeghs N, et al.
J Immunother Cancer
. 2024 Aug;
12(8).
PMID: 39107131
Background: Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies. This study evaluated the efficacy...
10.
Bonanni P, Maio M, Beretta G, Icardi G, Rossi A, Cinieri S
Vaccines (Basel)
. 2024 Apr;
12(4).
PMID: 38675802
Patients with cancer can be immunocompromised because of their disease and/or due to anticancer therapy. In this population, severe influenza virus infections are associated with an elevated risk of morbidity...